Strong Q2 Performance and Raised Guidance: Johnson & Johnson delivered robust Q2 2026 sales to customers of $25.3 billion, marking a 6.6% reported growth year-over-year and exceeding analyst expectations. This strong performance led to $5.53 billion in net earnings, and the company consequently raised its full-year 2026 guidance for both sales and adjusted EPS.
Innovative Medicine Drives Growth Amidst Headwinds: The Innovative Medicine segment remained the primary growth engine, contributing $16.4 billion in sales with 6.8% operational growth, fueled by strong performance in oncology and neuroscience, and key products like DARZALEX and TREMFYA. This growth was achieved despite a significant headwind from STELARA biosimilar competition; excluding STELARA, the business grew double digits.
MedTech Contributions and Strategic R&D Investments: The MedTech segment also contributed positively with $8.93 billion in sales, experiencing 3.6% operational growth across cardiovascular, surgery, vision, and orthopaedics. Johnson & Johnson continues to invest heavily in research and development, with total R&D expenses at $3.65 billion, notably $2.88 billion directed towards Innovative Medicine, and announced the planned acquisition of Firefly Bio to expand its oncology platform.
Robust Financial Position and Shareholder Returns: The company maintains a strong financial position, with $20.4 billion in cash and cash equivalents. Operating cash flows for the fiscal six months were robust at $11.13 billion, supporting $6.36 billion in dividends and $4.25 billion of share repurchases. Total long-term debt stood at $37.3 billion, with total assets of $201 billion.
On Track for $100 Billion Revenue Target and Future Catalysts: Management expressed confidence in achieving over $100 billion in annual revenue for the first time in the company's history in 2026, driven by diversified product strength and new launches. The company also highlighted several meaningful pipeline catalysts expected in the second half of the year.

Overall Takeaway
The Q2 fiscal 2026 earnings call was broadly positive. Johnson & Johnson demonstrated strong top-line growth that exceeded market expectations and, crucially, raised its full-year guidance, indicating continued momentum. Despite managing significant headwinds from STELARA biosimilar competition, the company showcased the strength of its diversified portfolio, particularly within the Innovative Medicine segment, and a healthy financial position to support future investments and shareholder returns.

Income Overview

Time Plot

Income Statement

Income Overview

Time Plot

Income Statement